Cancer drugs

Merck & Daiichi Sankyo’s $22 Billion Cancer Drug Deal; A Pioneering Partnership in Oncology

Merck & Co. has entered a substantial $22 billion agreement with Daiichi Sankyo, securing the rights to sell three experimental…